Chirurgische Therapie von Leber- und Pankreasmetastasen von Nierenzellkarzinomen

Bauschke, Astrid; Altendorf-Hofmann, A.; Deeb, Aladdin Ali; Kißler, H; Tautenhahn, Hans‐Michael; Settmacher, Utz

doi:10.1007/s00104-020-01331-3

Cited by 6 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results to breast cancer were achieved in radically resected ovarian cancer liver metastases with 5-and 10-year survival rates of 41% and 21%, respectively, and kidney cancer liver metastases with 5-and 10-year overall survival rates of 39% and 18%, respectively. These results are confirmed by others (Bauschke et al 2021;Zhuo et al 2020).…”

Section: Discussionsupporting

confidence: 90%

“…Most studies summarize a broad variety of cancer entities with differing prognosis to groups. Only for breast cancer (Feng et al 2020), kidney cancer (Bauschke et al 2021;Ruys et al 2011), gastric cancer (Luo et al 2019), and sarcoma (Grimme et al 2019) exist a small number of studies with adequate sample size to help clinicians to make a decision for or against surgical therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Surgical treatment of liver metastases from non-colorectal non-neuroendocrine carcinomas

Bauschke

Altendorf-Hofmann

Homman

et al. 2021

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

Introduction In the literature, results after surgical treatment of non-colorectal non-neuroendocrine liver metastases (NCNNLM) are reported that are often inferior to those from colorectal liver metastases. The selection of patients with favorable tumor biology is currently still a matter of discussion. Materials/methods The retrospective data analysis was based on data that were collected for the multicenter study “Role of surgical treatment for non-colorectal liver metastases” in county Thuringia. Results For the study, 637 patients were included from 1995 to 2018. 5 and 10-year survival of R0 resected patients were 33% and 19%, respectively. In the multi-variate analysis of the entire group, sex, timing, disease-free interval, number of metastases, R-classification as well as lymph node status of the primary lesion showed an independent statistical influence on the 5-year survival. In the group of R0 resected patients, disease-free interval, number of metastases and lymph node status of the primary lesion influenced the 5-year survival in the multi-variate analysis. In kidney malignancies, R-classification, timing and number of liver metastases were statistically significant in the multi-variate analysis of the 5-year survival, in mamma carcinomas only the R-classification. Conclusion The Adam score identifies some risk factors which influence prognosis in most but not in all tumor entities. For kidney cancer and breast cancer it can be simplified.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Surgical treatment of liver metastases from non-colorectal non-neuroendocrine carcinomas

Bauschke

Altendorf-Hofmann

Homman

et al. 2021

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…10a: 63% (median 69%) [254]. This also applies to the reports that additionally included cases with synchronously resected extrapancreatic metastases in their analyses [134,176,181,191,195,211,229,232,235,239,242,243] 88% [134]; 77% [176]; 63% [181], 79% [191], 72% [195], 50% [211], 72% [232], 79% [235], 81% [239], 68% [242], 83% [243], 77% [229]. 10a Schwarz 32%, Milanetto 55%: five-year SR 50%-88% (median 77%).…”

Section: Surgical Therapymentioning

confidence: 96%

Isolated Pancreatic Metastases of Renal Cell Carcinoma—Clinical Particularities and Seed and Soil Hypothesis

Sellner

Thalhammer

Klimpfinger

2023

Cancers

View full text Add to dashboard Cite

A meta-analysis of 1470 isolated pancreatic metastases of renal cell carcinoma revealed, that, in addition to the unusual exclusive occurrence of pancreatic metastases and the favourable treatment results, the isPMRCC is characterised by further peculiarities of the clinical course: The lack of prognostic significance of volume and growth rate dependent risk factors and the independence of treatment results from standard or local resections. As an explanation for all these peculiarities, according to today’s knowledge, a strong acting seed and soil mechanism can serve, which allows embolized tumour cells to grow to metastases only in the pancreas, and prevents them definitively or for years in all other organs. The good prognosis affects not only isolated PM, but also multi-organ metastases of the RCC, in which the additional occurrence of PM is also associated with a better prognosis. Genetic studies revealed specific changes in cases of PM of RCC: Lack of loss of 9p21.3 and 14q31.2, which are otherwise specific gene mutations at the onset of generalization, a low weight genome instability index, i.e., high genetic stability, and a low rate of PAB1 and a high rate of BPRM1 alterations, which signal a more favourable course. The cause of pancreatic organotropism in isPMRCC is still unclear, so only those factors that have been identified as promoting organotropism in other, more frequent tumour entities can be presented: Formation of the pre-metastatic niche, chemokine receptor–ligand mechanism, ability to metabolic adaptation, and immune surveillance.

show abstract

“…IsPMRCC are rare observations in which singular or multiple, synchronous or metachronous to the RCC distant metastases occur definitely or over a longer period exclusively in the pancreas. Since the last literature overview (n = 1034) covering the years 1952 to 2019 [51] a further 173 isPMRCC observations could be added [27,28,[52][53][54][55][56][57][58][59][60][61][62]. These 1207 observations serve as a basis for a literature review with meta-analysis.…”

Section: Clinical Presentationmentioning

confidence: 99%

Tumour Evolution and Seed and Soil Mechanism in Pancreatic Metastases of Renal Cell Carcinoma

Sellner

Thalhammer

Klimpfinger

2021

Cancers

View full text Add to dashboard Cite

In metastatic renal cell carcinoma, pancreatic metastases can appear in two clinical manifestations: (a) very rarely as isolated pancreatic metastases and (b) in the context with multi-organ metastatic disease. Both courses are characterised by rare, unusual clinical features. For isolated pancreatic metastases, the literature shows no effect on survival in all 11 publications that examined the effect of singular versus multiple pancreatic metastases; a lack of effect on survival time was also present in all 8 studies on pancreatic metastases size, in 7 of 8 studies on the influence of disease-free interval (DFI), and in 6 of 7 studies on the influence of synchronous versus metachronous metastases. In multi-organ site metastases observations, on the other hand, all five available references showed significantly better results in patients with concurrent pancreatic metastases compared to those without pancreatic metastases, although the total number of affected organs in the pancreatic metastases cohort was larger. Tumour volume-dependent risk factors thus remain surprisingly ineffective in both groups, which contradicts the usual behaviour of solid tumours. The reasons for this unusual behaviour and possible relations to tumour evolution and the hypothesis of an influence of a seed and soil mechanism in the occurrence of pancreatic metastases in metastatic renal cell carcinoma are discussed.

show abstract

Chirurgische Therapie von Leber- und Pankreasmetastasen von Nierenzellkarzinomen

Cited by 6 publications

References 29 publications

Surgical treatment of liver metastases from non-colorectal non-neuroendocrine carcinomas

Surgical treatment of liver metastases from non-colorectal non-neuroendocrine carcinomas

Isolated Pancreatic Metastases of Renal Cell Carcinoma—Clinical Particularities and Seed and Soil Hypothesis

Tumour Evolution and Seed and Soil Mechanism in Pancreatic Metastases of Renal Cell Carcinoma

Contact Info

Product

Resources

About